Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedernovartis.com
English RSS Feed
Get the latest updates from English RSS Feed directly as they happen.
Follow now 130 followers
Latest posts
Last updated 6 days ago
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
10 days ago
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement...
Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed
6 days ago
Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year...
Novartis verzeichnete im zweiten Quartal Umsatzsteigerungen und baute die Pipeline weiter aus; Prognose für das Geschäftsjahr bekräftigt
6 days ago
Novartis verzeichnete im zweiten Quartal Umsatzsteigerungen und baute die Pipeline weiter aus...
Novartis marks 30 years of breakthroughs, building on 250 years of discovery to reimagine what medicine can do next
12 days ago
Novartis marks 30 years of breakthroughs, building on 250 years of discovery...
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
10 days ago
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement...
Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients
21 days ago
Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with...
Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
25 days ago
Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)...
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
about 1 month ago
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy...
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
about 2 months ago
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD)...
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
about 2 months ago
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress...
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
about 2 months ago
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney...
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients
about 2 months ago
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained...